bioRxiv Science⌕ Search

Biology subjects

Rubanov, A.

Publications and source records attributed to Rubanov, A..

2 recordsLinked to original sources

MetFinder: a neural network-based tool for automated quantitation of metastatic burden in histological sections from animal models

Diagnosis of most diseases relies on expert histopathological evaluation of tissue sections by an experienced pathologist. By using standardized staining techniques and an expanding repertoire of markers, a trained eye is able to recognize disease-specific patterns with high accuracy and determine a diagnosis. As efforts to study mechanisms of metastasis and novel therapeutic approaches multiply, researchers need accurate, high-throughput methods to evaluate effects on tumor burden resulting from specific interventions. However, current methods of quantifying tumor burden are low in either resolution or throughput. Artificial neural networks, which can perform in-depth image analyses of tissue sections, provide an opportunity for automated recognition of consistent histopathological patterns. In order to increase the outflow of data collection from preclinical studies, we trained a deep neural network for quantitative analysis of melanoma tumor content on histopathological sections of murine models. This AI-based algorithm, made freely available to academic labs through a web-interface called MetFinder, promises to become an asset for researchers and pathologists interested in accurate, quantitative assessment of metastasis burden.

cancer biology↗

A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals

The emergence of novel SARS coronavirus 2 (SARS-CoV-2) in 2019 has triggered an ongoing global pandemic of severe pneumonia-like disease designated as coronavirus disease 2019 (COVID-19). To date, more than 2.1 million confirmed cases and 139,500 deaths have been reported worldwide, and there are currently no medical countermeasures available to prevent or treat the disease. As the development of a vaccine could require at least 12-18 months, and the typical timeline from hit finding to drug registration of an antiviral is >10 years, repositioning of known drugs can significantly accelerate the development and deployment of therapies for COVID-19. To identify therapeutics that can be repurposed as SARS-CoV-2 antivirals, we profiled a library of known drugs encompassing approximately 12,000 clinical-stage or FDA-approved small molecules. Here, we report the identification of 30 known drugs that inhibit viral replication. Of these, six were characterized for cellular dose-activity relationships, and showed effective concentrations likely to be commensurate with therapeutic doses in patients. These include the PIKfyve kinase inhibitor Apilimod, cysteine protease inhibitors MDL-28170, Z LVG CHN2, VBY-825, and ONO 5334, and the CCR1 antagonist MLN-3897. Since many of these molecules have advanced into the clinic, the known pharmacological and human safety profiles of these compounds will accelerate their preclinical and clinical evaluation for COVID-19 treatment.

microbiology↗